Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion.

A randomized prospective study on the effects of immediate provision of intrauterine contraception after first trimester induced abortion - effects on repeat abortions and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Dept Obstetrics and Gynecology, Helsinki University Central Hospital

Helsinki, 00029 HUS, Finland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Duration of pregnancy < 12 weeks.
Age ≥18 years

Exclusion criteria

Contraindication for spiral insertion: uterine anomaly, infection, copper allergy (Cu-IUD).

Treatment and study plan

Immediate intrauterine contraception

Device

A Cu-IUD or LNG-IUS is inserted after abortion.

Primary outcomes

Number of repeat abortions

Time frame: 5 years

Number of subsequent abortions during five years follow-up time.

Sponsors and collaborators

Lead sponsor

Helsinki University Central Hospital

Other

Collaborators

City of Helsinki

Registry information

Official study title

Systematic Provision of Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion. A Randomized, Prospective Trial.

Important dates

Study start: 2010
Primary completion: 2018
Study completion: 2018
First posted: Oct 19, 2010
Registry last updated: Aug 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed